title: Characterization of human flavin-containing monooxygenase (FMO) 3 and FMO5 expressed as maltose-binding protein fusions.
abstract: The flavin-containing monooxygenase (FMO) family of enzymes oxygenates nucleophilic xenobiotics and endogenous substances. Human FMO3 and FMO5 are the predominant FMO forms in adult liver. These enzymes are naturally membrane-bound, and recombinant proteins are commercially available as microsomal preparations from insect cells (i.e., Supersome FMO). As an alternative, FMO3 has previously been expressed as a soluble protein, through use of an N-terminal maltose-binding protein (MBP) fusion. In the current study, MBP fusions of both human FMO3 and FMO5 were prepared to >90% purity in the presence of detergent and characterized for biochemical and kinetic parameters, and the parameters were compared with those of Supersome FMO samples. Although MBP-FMO enzymes afforded lower rates of turnover than the corresponding Supersome FMOs, both types of FMO showed identical substrate dependencies and similar responses to changes in assay conditions. Of interest, the FMO3 enzymes showed a 2-fold activation of k(cat)/K(m) in the presence of Triton X-100. Oligomeric analysis of MBP-FMO3 also showed disassociation from a high-order oligomeric form to a monomeric status in the presence of Triton X-100. This report serves as the first direct comparison between Supersome FMOs and the corresponding MBP fusions and the first report of a detergent-based activation of k(cat)/K(m) that corresponds to changes in oligomerization.
authors.affiliation: Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA.
authors.forename: Robert R
authors.initials: RR
authors.lastname: Reddy
authors.forename: Erik C
authors.initials: EC
authors.lastname: Ralph
authors.forename: Meike S
authors.initials: MS
authors.lastname: Motika
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: John R
authors.initials: JR
authors.lastname: Cashman
mesh_terms: D006801:Humans; D007700:Kinetics; D058619:Maltose-Binding Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics*; D010105:Oxygenases / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis* / Q000737:chemistry / Q000302:isolation & purification
chemical_list: D058619:Maltose-Binding Proteins; D011993:Recombinant Fusion Proteins; D010105:Oxygenases; C020066:dimethylaniline monooxygenase (N-oxide forming)
references.citation: Protein Sci. 1999 Aug;8(8):1668-74
references.pmid: 10452611
references.citation: Drug Metab Dispos. 1997 Jul;25(7):790-7
references.pmid: 9224773
references.citation: Biol Pharm Bull. 2001 Nov;24(11):1263-6
references.pmid: 11725960
references.citation: Pharmacogenetics. 2003 Aug;13(8):495-500
references.pmid: 12893987
references.citation: Biochim Biophys Acta. 2005 Jan 17;1703(2):183-9
references.pmid: 15680226
references.citation: Chem Biol Interact. 1995 Apr 28;96(1):57-73
references.pmid: 7720105
references.citation: Chem Res Toxicol. 1990 Jul-Aug;3(4):372-6
references.pmid: 2133087
references.citation: Drug Metab Dispos. 2003 Jul;31(7):854-60
references.pmid: 12814961
references.citation: Biochem Pharmacol. 1998 Oct 15;56(8):1005-12
references.pmid: 9776311
references.citation: Pharmacol Ther. 2005 Jun;106(3):357-87
references.pmid: 15922018
references.citation: J Biochem Mol Toxicol. 2007;21(4):206-15
references.pmid: 17721934
references.citation: Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1507-21
references.pmid: 19040327
references.citation: Drug Metab Dispos. 1997 Aug;25(8):1001-7
references.pmid: 9280409
references.citation: Biochemistry. 1999 Apr 27;38(17):5588-95
references.pmid: 10220347
references.citation: Arch Biochem Biophys. 1972 May;150(1):116-25
references.pmid: 5028071
references.citation: Chem Biol Interact. 1997 Aug 29;106(1):29-45
references.pmid: 9305407
references.citation: Arch Biochem Biophys. 2010 Jan 1;493(1):26-36
references.pmid: 19944667
references.citation: Arch Biochem Biophys. 2007 Aug 15;464(2):251-9
references.pmid: 17531949
references.citation: Mol Pharmacol. 1990 May;37(5):643-51
references.pmid: 2338943
references.citation: Arch Biochem Biophys. 1984 Aug 15;233(1):50-63
references.pmid: 6087744
references.citation: Gen Pharmacol. 1991;22(3):549-52
references.pmid: 1651268
references.citation: J Biol Chem. 1993 Mar 5;268(7):5048-54
references.pmid: 8444881
references.citation: Arch Biochem Biophys. 2006 Jun 15;450(2):149-56
references.pmid: 16620765
references.citation: Mol Genet Metab. 2009 Jun;97(2):128-35
references.pmid: 19321370
references.citation: Expert Opin Drug Metab Toxicol. 2007 Dec;3(6):831-45
references.pmid: 18028028
references.citation: Methods Mol Biol. 2003;205:99-117
references.pmid: 12491882
references.citation: Drug Metab Dispos. 2006 Jan;34(1):19-26
references.pmid: 16183778
references.citation: J Pharmacol Exp Ther. 1999 Mar;288(3):1251-60
references.pmid: 10027866
references.citation: Methods Mol Biol. 2008;421:169-89
references.pmid: 18826055
references.citation: Drug Metab Dispos. 2008 Sep;36(9):1828-39
references.pmid: 18556438